©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Partial Inhibition of Na/K-ATPase by Ouabain Induces the Ca-dependent Expressions of Early-response Genes in Cardiac Myocytes (*)

(Received for publication, November 20, 1995; and in revised form, January 31, 1996)

Ming Peng Liuyu Huang Zijian Xie Wu-Hsiung Huang Amir Askari (§)

From the Department of Pharmacology, Medical College of Ohio, Toledo, Ohio 43699-0008

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES

ABSTRACT

Exposure of neonatal rat cardiac myocytes to ouabain concentrations that caused partial inhibition of Na/K-ATPase but no loss of viability, increased c-fos and c-jun mRNAs and the transcription factor AP-1. The increased mRNAs were proportional to the extent of inhibition of Na/K-ATPase and the resulting rise in steady state intracellular Ca concentration. The rapid and sustained increase of c-fos mRNA was shown to be due to increased transcriptional rate. Induction of c-fos by ouabain was prevented when either extracellular or intracellular Ca was lowered and was attenuated by pretreatment of myocytes with a phorbol ester under conditions known to down-regulate protein kinase C. Exposure to ouabain for 24-48 h also increased total transcriptional activity and protein content of myocytes. The findings suggest that the same signal responsible for the positive inotropic action of ouabain, i.e. net influx of Ca caused by partial inhibition of Na/K-ATPase, also initiates the rapid protein kinase C-dependent inductions of the early-response genes, the subsequent regulations of other cardiac genes by the resulting transcription factors, and stimulation of myocyte growth. Whether these hitherto unrecognized effects of cardiac glycosides are obtained in the intact heart and their relevance to the therapeutic uses of these drugs remain to be determined.


INTRODUCTION

Ouabain and related cardiac glycosides are highly specific inhibitors of Na/K-ATPase. This enzyme (the sodium pump) catalyzes the coupled active transport of Na and K across the plasma membranes of most animal cells (1) . It is now well established that the positive inotropic effect of a cardiac glycoside on the myocardium is due to the partial inhibition of the cardiac Na/K-ATPase, causing a small increase in intracellular Na, which in turn affects the sarcolemmal Na/Ca exchanger, leading to an increase in intracellular Ca and in the force of contraction(2, 3, 4) . This effect on cardiac contractility is the basis of the major therapeutic use of these drugs in the treatment of congestive heart failure(2, 3, 4) . There is also evidence to suggest that ouabain or related cardiac glycoside-like substances may be paracrine hormones in higher animals(5) .

In several cell types other than cardiac myocytes, inhibition of Na/K-ATPase, either by ouabain or by low extracellular K, has been shown to affect the expression of proto-oncogenes c-fos and c-jun(6, 7, 8) . Because the inductions of such early-response genes have been implicated in cardiac growth and hypertrophy(9, 10) , and since the hypertrophied failing heart is the primary target of therapy with cardiac glycosides, it was of interest to explore the effects of these drugs on the expressions of cardiac early-response genes. Here, we report the results of our initial studies in this direction, using the primary cultures of neonatal rat cardiac myocytes as a model.


EXPERIMENTAL PROCEDURES

Neonatal ventricular myocytes were prepared and cultured as described before(11, 12) . Briefly, myocytes were isolated from ventricles of 1-day-old Sprague-Dawley rats and purified by centrifugation on Percoll gradients. Myocytes were then cultured at a density of 5 times 10^4 cells/cm^2 in a medium containing four parts of DME (^1)and one part Medium 199 (Life Technologies, Inc.), penicillin (100 units/ml), streptomycin (100 µg/ml), and 10% fetal bovine serum. After 24 h of incubation at 37 °C in humidified air with 5% CO(2), the medium was changed to one with the same composition as above, but without the serum. Unless specified otherwise, all experiments were done at 37 °C after 24 h of additional incubation under serum-free conditions. These cultures contained more than 95% myocytes as assessed by immunofluorescence staining with a myosin heavy chain antibody(11) . For experiments on myocyte growth (Table 1) culture media also contained 0.1 mM bromodeoxyuridine during the first 48 h. The great majority of the serum-starved myocytes were quiescent or contracted infrequently(13) . Treatment with ouabain increased the number of myocytes beating regularly. No attempt was made to quantitate these effects on beating or on the contractile force. For some experiments with myocytes, the nominally Ca-free DME/F-12 base medium (Sigma) was used. Incubations of myocytes in this medium for the indicated short durations did not affect myocyte viability. Rat2 cells (CRL 1764, American Type Culture Collection) and HeLa cells were cultured in DME medium supplemented with 10% fetal bovine serum. The cells (about 90% confluence) were serum-starved for 24 h before use in experiments.



For Northern blot analysis, total RNA was isolated using TRI reagent (Molecular Research Center, Inc.) as recommended by the manufacturer. Routinely, 10-15 µg of total RNA was subjected to gel electrophoresis, transferred to a Nytran membrane, UV-immobilized, and hybridized to P-labeled probes. The probes used for c-fos, c-jun, and GAPDH were prepared as described before(11) . Autoradiograms obtained at -70 °C were scanned with a Bio-Rad densitometer. Multiple exposures were analyzed to ensure that the signals were within the linear range of the film. The relative amount of RNA in each sample was normalized to that of GAPDH mRNA to correct for differences in sample loading and transfer.

For nuclear run-on assays, myocyte nuclei were isolated as described by Lee et al. (14) and counted in 0.04% trypan blue using a hemocytometer. To label the nascent RNA transcripts, the nuclei (3 times 10^5) were incubated in 0.14 M KCl, 10 mM MgCl(2), 1 mM MnCl(2), 14 mM 2-mercaptoethanol, 20% glycerol, 0.2 M Tris (pH 8.0), 0.1 mg/ml creatine kinase, 10 mM phosphocreatine, 1 mM each of ATP, GTP, CTP, 0.03 µM UTP, and 100 µCi of [alpha-P]UTP (DuPont NEN, 3,000 Ci/mmol) for 15 min at 30 °C. The nuclei were collected, lysed, and digested with RNase-free DNase (Worthington). Fifty µg of carrier yeast tRNA were added, and the P-labeled run-on RNA produced was then isolated using TRI reagent (Molecular Research Center, Inc.). Purified [P]RNA was counted as an index of total transcriptional activity. Equal counts of P-labeled RNA from different groups were used for hybridization. The probes were applied to Nytran membrane through dot-blot apparatus, denatured, and immobilized by UV-cross-linking.

Electrophoretic mobility shift assay for AP-1 binding activity was done as described previously(11) . In brief, after myocyte nuclei were isolated, they were extracted in a solution containing 1.5 mM MgCl(2), 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride, 26% glycerol (v/v), 5 mM Hepes (pH 7.9), and 0.3 M NaCl. Nuclear protein (3-5 µg) was used in the binding reaction; the reaction mixture (20 µl) contained 50 mM NaCl, 1 mM EDTA, 1 µg of acetylated bovine serum albumin, 2 µg of poly(dI-dC), 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 10% glycerol (v/v), 5 mM MgCl(2), 10 mM Tris-HCl (pH 7.5), and about 30,000 cpm of P-labeled AP-1 probe. Control reaction mixtures for the detection of specific binding contained 100-fold excess of unlabeled probe. DNA-protein complexes were separated on nondenaturing 4.5% polyacrylamide gels in 90 mM Tris borate, 2 mM EDTA (pH 8.0). Gels were vacuum-dried and exposed to x-ray film at -70 °C for 12 to 24 h. The oligonucleotide probe for AP-1 was synthesized according to the sequences as described by Meyer et al. (15) and labeled by T4 DNA kinase using [-P]ATP.

Intracellular Ca concentration was determined using the Ca-sensitive fluorescent probe fura-2 as we have previously described(16) . Briefly, the myocytes were cultured on glass coverslips and loaded with 5 µM fura-2/AM for 30 min at room temperature. The coverslip was affixed to a culture chamber and perfused for 15 min with the medium containing the indicated ouabain concentration before measurements were made on about 20 single cells. A single cell was isolated from the surrounding area using a pinhole aperture under Nikon microscope, and single cell fluorescence was recorded at an emission wavelength of 505 nm and excitation wavelengths of 340/380 nm using Spex Fluoro II dual beam spectrofluorometer (Spex Industries, Inc.). Measurement of time-averaged signals on each single cell was completed in 30 s. The relationship between the fluorescence ratio (340/380) and steady state Ca concentration was established by calibration procedures and calculations described before (16, 23) . Because of the well-known uncertainties associated with such calibrations, however, the indicated values should be considered as relative changes in intracellular Ca concentrations.

For the assay of Rb uptake, myocytes cultured in 12-well plates were washed and incubated in 1.0 ml of uptake medium containing 150 mM NaCl, 5 mM RbCl, 10 mM Hepes (pH 7.0), 5 mM MgCl(2), 0.5 mM CaCl(2), and 10 mM glucose. After 10 min of incubation with different concentrations of ouabain, Rb uptake was started by the addition of 1 µCi of Rb, and the reaction was stopped after 10 min by washing four times with 3 ml of ice-cold 0.1 M MgCl(2). The cells were then treated with 10% trichloroacetic acid at 4 °C for 60 min, and trichloroacetic acid-soluble Rb was counted. Trichloroacetic acid-precipitated cellular protein was dissolved in 0.1 N NaOH, and protein content was determined(17) , using bovine serum albumin as standard. DNA was assayed fluorometrically (48) using calf thymus DNA as standard. Myocyte viability was assayed by the extent of release of LDH into the medium(11) .


RESULTS

Ouabain Effects on Myocyte Viability, Rb Uptake, and Intracellular Ca

Time courses of the effects of different ouabain concentrations on the viability of the serum-starved myocytes were studied in experiments, the results of which are summarized in Fig. 1. At concentrations of 0.1 mM or less, ouabain did not affect viability up to 24 h of incubation. At higher ouabain concentrations, there was time-dependent loss of viable cells. These data were used as a guide for the remaining experiments on myocytes; i.e. when ouabain concentrations higher than 0.1 mM were used, exposure times did not exceed 45 min. Hence, there was no significant ouabain-induced decrease in the number of viable cells in any of the experiments presented below.


Figure 1: Time courses of the effects of different ouabain concentrations on myocyte viability. Myocytes were prepared and incubated at 37 °C in the presence of indicated ouabain concentrations as described under ``Experimental Procedures.'' At indicated times, loss of viability was measured by the assay of released lactic dehydrogenase. Values are mean ± S.E. of 5 different experiments. S.E. not shown when smaller than symbol size.



Inhibitory effects of different ouabain concentrations on Rb uptake, and on intracellular Ca concentrations, were determined in experiments shown in Fig. 2. Our findings on inhibition of Rb uptake were in general agreement with previous observations on dose-dependent inhibitory effects of ouabain on pump fluxes in rat neonatal cardiac myocytes (18, 19) and on Na/K-ATPase activities of these myocytes and the rat heart(2, 20) .


Figure 2: Effects of different ouabain concentrations on Rb uptake by myocytes and on intracellular Ca concentrations. Rb uptake was assayed as described under ``Experimental Procedures.'' The values are means ± S.E. of 6 different experiments. Assays of intracellular Ca were done in separate experiments as described under ``Experimental Procedures.'' Values are means ± S.E. of 40-60 single cell determinations at each ouabain concentration, using 4 different myocyte preparations.



As expected from a large body of previous work relating ouabain-induced inhibition of the cardiac sodium pump to intracellular Ca(2, 3, 4, 21, 22, 23) , our data showed significant increases in intracellular Ca concentrations of these myocytes in parallel with ouabain-induced inhibition of Rb uptake (Fig. 2).

The following aspects of the data of Fig. 1and Fig. 2are worthy of note at this point. 1) That complete inhibition of pump-mediated Rb uptake requires 1 mM or higher concentrations of ouabain (Fig. 2) is consistent with the fact that of the two isoforms (alpha(1) and alpha(3)) of Na/K-ATPase present in neonatal rat cardiac myocytes, the predominant one is the relatively ouabain insensitive alpha(1) isoform(24, 25) . 2) The observation that 0.1 mM ouabain causes significant inhibition of the pump (Fig. 2) without affecting myocyte viability (Fig. 1) is consistent with the well-established fact that the heart tolerates up to about 50% inhibition of Na/K-ATPase without overt toxicity(3) .

Inductions of Myocyte c-fos and c-jun by Ouabain

Effects of the exposure of a myocyte preparation to different ouabain concentrations for 45 min on c-fos and c-jun mRNAs are shown in Fig. 3A. Experiments similar to this were repeated in several different preparations, and the results were combined as shown in Fig. 3B. The data clearly indicate that ouabain increased both messages in a dose-dependent manner. These dose-response curves are in good agreement with ouabain's dose-response curves on rat cardiac contractility(2) , rat cardiac sarcolemmal Na/K-ATPase(2) , and Na/K-ATPase of rat neonatal cardiac myocytes (20) . That ouabain's effect on c-fos was more pronounced than that on c-jun (Fig. 3B) is similar to the differential effects of other stimuli (e.g.(11) ) on c-fos and c-jun expressions in cardiac myocytes. When time-dependent changes in c-fos mRNA in response to 0.1 mM ouabain were measured (Fig. 4), a significant increase was noted within 15 min after exposure, the maximal increase was obtained at 3 h, and the level gradually declined to that of control after 24 h of continuous exposure to ouabain.


Figure 3: Dose-response curve of ouabain effects on c-fos and c-jun expressions in myocytes. A, a representative autoradiogram of ouabain effects. Serum-starved myocytes were incubated at 37 °C for 45 min with the following ouabain concentrations (µM): lane 1, 0; lane 2, 0.5; lane 3, 5; lane 4, 50; lane 5, 100; lane 6, 500. Total RNA was isolated and subjected to Northern blot analysis as described under ``Experimental Procedures.'' B, combined data from several different experiments. c-fos and c-jun mRNAs were normalized to those of corresponding GAPDH measured on the same blot and expressed relative to a control value of one.




Figure 4: Time course of ouabain-induced c-fos expression. Myocytes were treated with 100 µM ouabain and assayed for c-fos mRNA as indicated in Fig. 3after the following incubation times: lane 1, 0; lane 2, 15 min; lane 3, 45 min; lane 4, 90 min; lane 5, 3 h; lane 6, 6 h; lane 7, 18 h; lane 8, 24 h.



It was of interest to know if the above ouabain effects on serum-starved myocytes were also observed in the presence of serum. Comparison of ouabain effects on c-fos mRNA in cells cultured for 48 h in the presence of serum, with the effects in our standard myocyte preparation (24 h in serum-containing medium, followed by 24 h in serum-free medium) showed nearly identical results (Fig. 5). When serum-starved cells were exposed for 45 min to 0.1 mM ouabain, or 10% fetal bovine serum, or the combination of the two, ouabain-induced increase in c-fos mRNA was greater than that caused by serum, and the combined effects of the two agents were not greater than that of ouabain alone (data not shown). All remaining experiments were done with the serum-starved myocytes to minimize contamination by other cell types (see ``Experimental Procedures'').


Figure 5: Comparison of ouabain effects on myocyte c-fos expression in serum-free and serum-containing media. Ouabain effects were determined either on serum-starved myocytes as in Fig. 3or on myocytes similarly cultured in the presence of serum. Values are mean ± S.E. of 3 determinations.



The nuclear run-on experiments of Fig. 6showed that ouabain-induced increase in steady state concentrations of c-fos mRNA was due, at least in part, to increase in transcriptional rate of c-fos.


Figure 6: Nuclear run-on experiments showing ouabain effects on c-fos transcription rate. Incubations were done in the presence of 0.5 mM ouabain and in its absence for 45 min as in Fig. 3. Nuclei were then isolated from myocytes, labeled with [alpha-P]UTP, and hybridized with c-fos, GAPDH, and pKs (pUC19) probes. Inset, a representative autoradiogram: lane 1, control myocytes; lane 2, ouabain-treated myocytes. Combined data (mean ± S.E.) from 4 different experiments are shown in the graph. The intensities of the signals of c-fos and GAPDH were corrected by subtracting signals of pKs, and the values of c-fos signals were normalized to those of corresponding GAPDH signals.



To determine if the above inductions were accompanied by the formation of AP-1, containing Fos and Jun and capable of binding to DNA, nuclear extracts of control and ouabain-exposed myocytes were subjected to mobility shift assays. The results (Fig. 7) showed that ouabain increased a nuclear protein that could bind to a probe containing the AP-1 binding site. In experiments the results of which are not shown, we also noted that the nuclei of myocytes treated with ouabain contained significantly more Fos and Jun proteins than control nuclei, as determined by immunostaining procedures that we have used before to show the inductions of these proteins by other stimuli (11) .


Figure 7: Activation of AP-1 by ouabain in myocytes. Nuclear extracts were prepared from myocytes after treatment with 0.1 mM ouabain for 2 h, incubated with P-labeled oligonucleotide encompassing the AP-1 motif, and subjected to mobility shift assays. Lanes 1 and 2, control; lanes 3 and 4, ouabain-treated. Lanes 1 and 3, P-labeled probe; lanes 2 and 4, labeled probe plus 100-fold excess of unlabeled probe.



Dependence of Ouabain-induced c-fos Expression on Ca and PKC

Ouabain effect on c-fos mRNA was blocked when myocytes were pretreated with cell permeant BAPTA-AM to buffer intracellular Ca (Fig. 8). Pretreat with BAPTA-AM, which has been shown to block phenylephrine's effect on c-fos expression(28) , also blocked the effect of PMA on c-fos expression (Fig. 8). This suggests a role of intracellular Ca in the pathways of the effects of ouabain, phenylephrine, and PMA on c-fos. When myocytes were incubated in a nominally Ca-free medium, ouabain had no effect on expression of c-fos mRNA, whereas phenylephrine and PMA, two well-established inducers of c-fos(12, 26) , remained effective (Fig. 9). Addition of Ca to the medium restored the effect of ouabain (Fig. 9), clearly establishing the necessity of ouabain-induced net influx of extracellular Ca for ouabain's effect on c-fos. In similar experiments (not shown), it was established that repletion of medium Ca did not have a significant effect on phenylephrine's or PMA's effect on c-fos expression. Evidently, the effects of these stimuli do not require the influx of extracellular Ca.


Figure 8: Effects of BAPTA-AM preloading of myocytes on inductions of c-fos by ouabain and PMA. Control cells and cells that were pretreated with 10 µM BAPTA-AM for 30 min were exposed to 0.5 mM ouabain or 0.1 µM PMA for 45 min. c-fos mRNA was measured and normalized to those of GAPDH. The values are mean ± S.E. of 5 experiments.




Figure 9: Effect of extracellular Ca on ouabain-induced increase in c-fos mRNA. Serum-starved myocytes were placed in a nominally Ca, Mg-free medium (see ``Experimental Procedures'') supplemented with 1.2 mM Mg and 0.1 mM EGTA. Effects of 0.5 mM ouabain, 0.1 mM phenylephrine, and 0.1 µM PMA after 45 min of incubation in this Ca-free medium were determined. Ouabain effects were also determined after similar incubation in the same medium to which 1.8 mM Ca was also added. Values are means ± S.E. of 3 experiments.



Preincubation of myocytes with PMA for 24 h, which is known to down-regulate PKC in these cells(27, 28) , suppressed ouabain-induced c-fos expression (Fig. 10), indicating an important role of one or more isoforms of PKC in the pathway of response to ouabain.


Figure 10: Effect of pretreatment with PMA on ouabain-induced expression of c-fos mRNA. Control myocytes and those treated with 0.1 µM PMA for 24 h were exposed to 0.1 mM or 0.5 mM ouabain for 45 min and assayed for c-fos mRNA as in Fig. 3. Values are mean ± S.E. of 6 experiments.



Ouabain Effects on Total Myocyte Protein and Transcriptional Activity

Since many of the stimuli that induce early-response genes also cause hypertrophic growth of cardiac myocytes(10, 29, 30) , we compared the effects of ouabain with those of phenylephrine and PMA on myocyte protein content (Table 1). The large increases caused by phenylephrine and PMA were in agreement with previous observations(26) . The increase in total protein caused by ouabain was significant but smaller than those caused by phenylephrine and PMA. Experiments of Fig. 11showed that total transcriptional activity was also increased significantly after 24 h of exposure of myocytes to 0.1 mM ouabain.


Figure 11: Effect of ouabain on total transcriptional activity of myocytes. Cells were incubated in the presence of 0.1 mM ouabain and in its absence for 24 h. Nuclei were prepared and subjected to run-on transcriptional analysis as described under ``Experimental Procedures.'' Values are mean ± S.E. of 5 experiments (p < 0.05).



Ouabain Effects on c-fos Expression in HeLa and Rat2 Cells

Previous studies of Nakagawa et al.(6) showed that ouabain-induced increases in c-fos and c-jun transcriptions in several human cell lines (e.g. HeLa cells), and in mouse fibroblasts, required ouabain concentrations that cause complete inhibition of Na/K-ATPase. Our experiments on c-fos expression in HeLa cells confirmed their findings. A ouabain-induced increase in c-fos mRNA required 3-4 h of exposure to 1 µM or higher concentrations of ouabain, and the maximal level of mRNA was about 15-fold greater than the control level. HeLa cells contain a highly ouabain-sensitive isoform of Na/K-ATPase that is almost completely inhibited at 1 µM ouabain(31) . We also did limited studies to compare ouabain's effects on cardiac myocytes with those on Rat2 fibroblasts. This cell line's only Na/K-ATPase isoform is the same relatively ouabain-resistant alpha(1) that exists in rat cardiac myocytes. (^2)The results of these experiments showed that (a) ouabain concentrations of 0.5 mM or higher were required to note an increase in c-fos mRNA and (b) the maximal level of c-fos mRNA, about 5 times that of control, was obtained after 15 min of exposure to ouabain and rapidly declined to control level after about 1 h of exposure. Thus, ouabain effects on c-fos of these fibroblasts differed greatly, both in magnitude and duration, from those noted in myocytes ( Fig. 3and Fig. 4).


DISCUSSION

The data presented here show that in neonatal rat cardiac myocytes: (a) the proto-oncogenes c-fos and c-jun are rapidly induced by ouabain concentrations that inhibit the sodium pump partially and raise intracellular Ca, but do not cause loss of viability, (b) the sustained induction of c-fos is dependent on extracellular Ca and its net influx is due to ouabain-induced inhibition of the pump, (c) PKC is likely to be involved in this pathway of ouabain-induced gene regulation, and (d) along with the above effects, ouabain stimulates the growth of these myocytes.

Cardiac Specificity of Ouabain Effects on Early-response Genes

Nakagawa et al.(6) were the first to report the transcriptional regulation of early-response genes by ouabain. Their studies on HeLa and some other cell lines showed that increased expressions of c-fos and c-jun required several hours of exposure to ouabain concentrations that cause near complete inhibition of Na/K-ATPase. Our limited experiments on HeLa cells (see ``Results'') have confirmed their findings. Nakagawa et al.(6) also noted that in these cell lines, ouabain-induced expression of c-fos was neither Ca-dependent nor affected by depletion of PKC. It is clear, therefore, that the slow induction of the genes by the toxic concentrations of ouabain in the cells used by these investigators occur through mechanisms different from the ouabain-induced pathways in cardiac myocytes. More recently, Golomb et al.(7) reported that in vascular smooth muscle cells, ouabain did not affect the expression of c-fos in the absence of serum, but that the mitogenic effects of serum, including the inductions of early-response genes, were enhanced by ouabain. In cardiac myocytes, however, ouabain-induced regulation of c-fos is independent of serum (Fig. 5), and no synergistic effects of serum and ouabain are apparent (see ``Results''). To our knowledge, the only other prior report relating the early-response genes to the sodium pump is that of Cayanis et al.(8) , in which the inhibition of sodium pump by low extracellular K was shown to cause a modest, rapid, and transient increase in c-fos mRNA in a liver cell line. This pattern, and a similar one that we observed in Rat2 fibroblasts (see ``Results''), also differ from the large and sustained ouabain-induced increases in c-fos mRNA in cardiac myocytes ( Fig. 3and Fig. 4). Clearly, based on available evidence, there seem to be cardiac-specific regulatory effects of ouabain on expressions of proto-oncogenes.

Comparison of Ouabain with Other Inducers of Cardiac Early-response Genes

A number of stimuli induce early-response genes in cultured cardiac myocytes(9, 10) , including alpha- and beta-adrenergic agonists (12, 30) , angiotensin II(32) , stretch(33) , endothelin(34) , purinergic receptor agonists(35) , phorbol esters(26) , hypoxia(36) , and oxidants(11) . Examination of this literature shows differences between ouabain effects and those of any other stimulus. The evident differences are either quantitative, or qualitative, or both. For example, the magnitude of the increase in c-fos mRNA induced by ouabain in neonatal myocytes is matched only by that of PMA ( Fig. 9and (26) ), and, while the effects of ouabain and phenylephrine on c-fos are regulated by intracellular Ca concentrations and PKC ( Fig. 8and Fig. 10, and (28) ), only ouabain's effect, but not that of phenylephrine, is dependent on the net influx of extracellular Ca ( Fig. 9and ``Results''). Interestingly, ATP, which also causes a net influx of Ca, albeit by a mechanism different from that of ouabain (37) , has a much smaller effect on c-fos mRNA (35) than that of ouabain. These and other similarities and differences between the various regulators of cardiac early-response genes point to the existence of both conserved and divergent pathways of early-response gene regulation and the need for the identification of control mechanisms specific to each stimulus.

Mechanisms of Ouabain Effects on c-fos Expression

Although ouabain's effects are evident on both c-fos and c-jun, we have focused most of our initial studies on c-fos due to the wealth of knowledge on the regulatory mechanisms of this gene and because the magnitude of ouabain effect on c-fos mRNA is about 10-fold greater than that on c-jun mRNA (Fig. 3).

An important question is whether the rise in intracellular Ca that is the well-established result of the partial inhibition of cardiac Na/K-ATPase (2, 3, 4) can account for the observed induction of c-fos by ouabain. The c-fos promoter contains two well-characterized elements, SRE and Ca response element/cAMP response element, one or both of which are known to be regulated by rise in intracellular Ca in various cells including neonatal rat cardiac myocytes(33, 38, 39) . Since induction of c-fos by ouabain involves PKC (Fig. 10), and SRE is known to be stimulated by PKC(38, 40) , it seems that ouabain induction of c-fos may be, at least in part, through SRE. However, because of the complex and multiple mechanisms of Ca effects on the activations of the above two elements of the c-fos gene(38, 39, 41) , our present data are insufficient either to establish the definite involvement of SRE or to rule out the role of Ca response element/cAMP response element in c-fos induction by ouabain. Studies aimed at clarification of these issues are in progress.

There is uncertainty regarding the mechanism of PKC activation in the course of induction of c-fos by ouabain. Although increased intracellular Ca may cause direct activation or redistribution of PKC isoforms(28, 42) , it is not clear that ouabain-induced increase in myocyte Ca is responsible for PKC activation. Previous studies have demonstrated that both inotropic and toxic concentrations of ouabain enhance phosphoinositide turnover, increase diacylglycerol content, and activate PKC in the myocardium (43, 44) . While these effects may be the consequence of activation of phospholipase C by ouabain-induced increases in intracellular Ca(43) , there is also some evidence to suggest that activation of PKC by ouabain may occur by unidentified mechanisms that are independent of a ouabain-induced rise in intracellular Ca(44) .

Based on the above considerations, it is reasonable to conclude that the same signal (increased net influx of Ca) that accounts for the classical effect of ouabain on contractility is also responsible for the initiation of ouabain effect on c-fos expression, but that additional pathways independent of the rise in intracellular Ca may also be involved in response of the c-fos to ouabain.

Ouabain's Effect on Myocyte Growth

Our findings ( Table 1and Fig. 11) clearly show that ouabain, like most other inducers of cardiac early-response genes, increases protein content and stimulates myocyte growth. At first sight, these findings may seem to be in conflict with some previous observations. There is a large body of older literature (45) showing inhibitory effects of ouabain on transformation and proliferative growth of several mammalian cell types and indicating the important role of the sodium pump in these processes. Examination of this literature reveals that these effects of ouabain are accompanied by significant dissipation of the normal Na and K gradients and are most likely due to the well-established inhibitory effects of low intracellular K on protein synthesis(45) . There are also limited data showing that in ferret papillary muscle, ouabain reduced protein synthesis, in contrast to several other inotropic agents that stimulated protein synthesis (46) . The ferret heart contains nearly equal amounts of two isoforms of the sodium pump, one of which is highly sensitive to ouabain(47) . Based on the ouabain sensitivity of total Na/K-ATPase of ferret heart(47) , it seems likely that the noted ouabain inhibition of protein synthesis (46) was also due to large changes in intracellular Na and K. It is well established that when the myocardium is exposed to inotropic but nontoxic ouabain concentrations, a significant increase in intracellular Ca is obtained without large changes in intracellular Na and K concentrations(2, 3, 4, 21, 22, 23) . We suggest that the primary effect of such lower concentrations of ouabain on protein synthesis and myocyte growth will be stimulatory as in experiments of Table 1.

Extensive studies on hypertrophic growth of cardiac myocytes have shown that contraction stimulates growth(48, 49) , but that for some stimuli induction of growth is independent of the enhancement of contractility (30, 49) . It is also well-established that cardiac hypertrophy caused by many stimuli is associated with the selective induction of the fetal gene program(29, 30) . In these contexts, we do not have sufficient data to compare ouabain with other hypertrophic stimuli. In our experiments, ouabain clearly affected myocyte contractility as expected (see ``Experimental Procedures''), although we did not quantitate these effects. It remains to be seen if ouabain's effect on growth can be distinguished from its effects on contractility. Studies are also in progress to determine whether or not ouabain exerts selective effects on the cardiac fetal gene program.

Physiological and Therapeutic Implications

Studies similar to those reported here need to be done with the heart, because there are significant differences between the responses of cultured myocytes and isolated heart preparations to some, but not all, inducers of cardiac early-response genes(50) . Assuming that the present findings may be extrapolated to the intact heart, however, ouabain's rapid effects on the early-response genes, and the transcription factor AP-1, suggest that soon after its effect on contractility, ouabain begins to exert potentially profound effects on the expressions of a multitude of cardiac proteins. AP-1 and related proto-oncogene products have been shown to regulate several cardiac genes, including those of contractile proteins(51, 52, 53) . The sodium pump genes also contain AP-1 or related binding elements(54, 55) , and these have been implicated in the control of pump expression in liver cells(56) . Since partial inhibition of the sodium pump by ouabain is known to cause a subsequent increase in functional pump sites in cardiac myocytes(57, 58) , it is reasonable to think that the adaptive induction of cardiac sodium pump may also be a consequence of ouabain-induced stimulation of AP-1. Ouabain's apparent effect on myocyte growth raises intriguing questions about the chronic treatment of the hypertrophied failing heart with a hypertrophic stimulus. Until the nature of these previously unrecognized effects of cardiac glycosides are clarified, it is not possible to say whether they are a part of the beneficial or the undesirable effects of these drugs. These questions may be pertinent to the current efforts to reassess the value of cardiac glycosides and related drugs for the treatment of congestive heart failure(59) .


FOOTNOTES

*
This work was supported by National Institutes of Health Grant HL-36573 awarded by NHLBI, United States Public Health Service, Department of Health and Human Services. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept. of Pharmacology, Medical College of Ohio, P. O. Box 10008, Toledo, OH 43699-0008. Tel.: 419-381-4182; Fax: 419-381-2871.

(^1)
The abbreviations used are: DME, Dulbecco's modified Eagle's medium; AP-1, activator protein 1; BAPTA-AM, bis(o-aminophenoxy)ethane-N,N,N`,N`-tetraacetic acid-tetra(acetoxymethyl) ester; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PKC, protein kinase C; PMA, phorbol 12-myristate 13-acetate; SRE, serum response element.

(^2)
N. Zolotarjova, Z. Xie, W.-H. Huang, and A. Askari, unpublished observations.


REFERENCES

  1. Lingrel, J. B., and Kuntzweiler, T. (1994) J. Biol. Chem. 269, 19659-19662 [Free Full Text]
  2. Schwartz, A., Grupp, G., Wallick, E., Grupp, I. L., and Ball, Jr., W. J. (1988) Prog. Clin. Biol. Res. 268B, 321-338
  3. Akera, T., and Ng, Y. C. (1991) Life Sci. 48, 97-106 [CrossRef][Medline] [Order article via Infotrieve]
  4. Eisner, D. A., and Smith, T. W. (1992) in The Heart and Cardiovascular System (Fozzard, H. A., Haber, E., Jennigs, R. B., Katz, A. M., and Morgan, H. E., eds) 2nd Ed., Vol. 1, pp. 863-902, Raven Press, New York
  5. Blaustein, M. P. (1993) Am. J. Physiol. 264, C1367-C1387
  6. Nakagawa, Y., Rivera, V., and Larner, A. C. (1992) J. Biol. Chem. 267, 8785-8788 [Abstract/Free Full Text]
  7. Golomb, E., Hill, M. R., Brown, R. B., and Keiser, H. R. (1994) Am. J. Hypertens. 7, 69-74 [Medline] [Order article via Infotrieve]
  8. Cayanis, E., Russo, J. J., Wu, Y. S., and Edelman, I. S. (1992) J. Membr. Biol. 125, 163-170 [Medline] [Order article via Infotrieve]
  9. Parker, T. G., and Schneider, M. D. (1991) Annu. Rev. Physiol. 53, 179-200 [CrossRef][Medline] [Order article via Infotrieve]
  10. van Bilsen, M., and Chien, K. R. (1993) Cardiovasc. Res. 27, 1140-1149 [Medline] [Order article via Infotrieve]
  11. Peng, M., Huang, L., Xie, Z.-J., Huang, W.-H., and Askari, A. (1995) Cell. Mol. Biol. Res. 41, 189-197 [Medline] [Order article via Infotrieve]
  12. Iwaki, K., Sukhatme, V. P., Shubeita, H. E., and Chien, K. R. (1990) J. Biol. Chem. 265, 13809-13817 [Abstract/Free Full Text]
  13. Simpson, P. (1985) Circ. Res. 56, 884-894 [Abstract]
  14. Lee, H. R., Henderson, S. A., Reynolds, R., Dunnmon, P., Yuan, D., and Chien, K. R. (1988) J. Biol. Chem. 263, 7352-7358 [Abstract/Free Full Text]
  15. Meyer, M., Schreck, R., and Baeuerle, P. A. (1993) EMBO J. 12, 2005-2015 [Abstract]
  16. Lachant, N. A., Smith, M. R., Xie, Z.-J., and Romani, W. R. (1995) Am. J. Hematol. 49, 56-66 [Medline] [Order article via Infotrieve]
  17. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275 [Free Full Text]
  18. McCall, D. (1979) Am. J. Physiol. 236, C87-C95
  19. Heller, M., Hallaq, H., and Panet, R. (1988) Biochim. Biophys. Acta 939, 595-602 [Medline] [Order article via Infotrieve]
  20. Xie, Z., Wang, Y., Ganjeizadeh, M., McGee, R., and Askari, A. (1989) Anal. Biochem. 183, 215-219 [Medline] [Order article via Infotrieve]
  21. Biedert, S., Barry, W. H., and Smith, T. W. (1979) J. Gen. Physiol. 74, 479-494 [Abstract]
  22. Barry, W. H., Hasin, Y., and Smith, T. W. (1985) Circ. Res. 56, 231-241 [Abstract]
  23. Kim, D., Cragoe, E. J., Jr., and Smith, T. W. (1987) Circ. Res. 60, 185-193 [Abstract]
  24. Orlowski, J., and Lingrel, J. B. (1990) J. Biol. Chem. 265, 3462-3470 [Abstract/Free Full Text]
  25. Arystarkhova, E., and Sweadner, K. (1994) in The Sodium Pump (Bamberg, E., and Schoner, W., eds) pp. 230-233, Steinkopff-Verlag, Darmstadt, FRG
  26. Dunnmon, P. M., Iwaki, K., Henderson, S. A., Sen, A., and Chien, K. R. (1990) J. Mol. Cell. Cardiol. 22, 901-910 [Medline] [Order article via Infotrieve]
  27. Henrich, C. J., and Simpson, P. C. (1988) J. Mol. Cell. Cardiol. 20, 1981-1085
  28. Puceat, M., Hilal-Dandan, R., Strulovici, B., Brunton, L. L., and Brown, J. H. (1994) J. Biol. Chem. 269, 16938-16944 [Abstract/Free Full Text]
  29. Chien, K. R., Zhu, H., Knowlton, K. U., Miller-Hance, W., van-Bilsen M., O'Brien, T. X., and Evans, S. M. (1993) Annu. Rev. Physiol. 55, 77-95 [CrossRef][Medline] [Order article via Infotrieve]
  30. Simpson, P. C., Kariya, K.-I., Karns, L. R., Long, C. S., and Karliner, J. S. (1991) Mol. Cell. Biochem. 104, 35-43 [Medline] [Order article via Infotrieve]
  31. Price, E. M., and Lingrel, J. B. (1988) Biochemistry 27, 8400-8408 [Medline] [Order article via Infotrieve]
  32. Sadoshima, J. I., and Izumo, S. (1993) Circ. Res. 73, 424-438 [Abstract]
  33. Sadoshima, J. I., and Izumo, S. (1993) EMBO J. 12, 1681-1692 [Abstract]
  34. Shubeita, H. E., McDonough, P. M., Harris, A. N., Knowlton, K. U., Glembotski,C. C., Brown, J. H., and Chien, K. R. (1990) J. Biol. Chem. 265, 20555-20562 [Abstract/Free Full Text]
  35. Zheng, J.-S., Boluyt, M. O., O'Neill, L., Crow, M. T., and Lakatta, E. G. (1994) Circ. Res. 74, 1034-1041 [Abstract]
  36. Webster, K. A., Discher, D. J., and Bishopric, N. J. (1993) J. Biol. Chem. 268, 16852-16858 [Abstract/Free Full Text]
  37. Puceat, M., Clement, O., Scamps, F., and Vassort, G. (1991) Biochem. J. 274, 55-62 [Medline] [Order article via Infotrieve]
  38. Lee, G., and Gilman, M. (1994) Mol. Cell. Biol. 14, 4579-4587 [Abstract]
  39. Thompson, M. A., Ginty, D. D., Bonni, A., and Greenberg, M. E. (1995) J. Biol. Chem. 270, 4224-4235 [Abstract/Free Full Text]
  40. Cobb, M. H., and Goldsmith, E. J. (1995) J. Biol. Chem. 270, 14843-14846 [Free Full Text]
  41. Miranti, C. K., Ginty, D. D., Huang, G., Chatila, T., and Greenberg, M. E. (1995) Mol. Cell. Biol. 15, 3672-3684 [Abstract]
  42. Brown, J. H., and Martinson, E. A. (1992) Trends Cardiovasc. Med. 2, 209-214
  43. Otani, B., Otani, H., Morita, M., and Das, D. K. (1989) Mol. Cell. Biochem. 90, 111-120 [Medline] [Order article via Infotrieve]
  44. Gotoh, H., Kamiyama, A., Shibayama, R., Sawada, M., and Kashimoto, T. (1993) Biochem. Biophys. Res. Commun. 194, 72-78 [CrossRef][Medline] [Order article via Infotrieve]
  45. Kaplan, J. G. (1978) Annu. Rev. Physiol. 40, 19-41 [CrossRef][Medline] [Order article via Infotrieve]
  46. Kent, R. L., Hoober, K. H., and Cooper, G. (1989) Circ. Res. 64, 74-85 [Abstract]
  47. Ng, Y.-C., and Akera, T. (1987) Am. J. Physiol. 252, H1016-H1022
  48. McDermott, P. J., and Morgan, H. E. (1989) Circ. Res. 64, 542-553 [Abstract]
  49. Allo, S. N., Carl, L. L., and Morgan, H. E. (1992) Am. J. Physiol. 263, C319-C325
  50. Schunkert, H., Sadoshima, J.-I., Cornelius, T., Kagaya, Y., Weinberg, E. O., Izumo, S., Riegger, G., and Lorell, B. H. (1995) Circ. Res. 76, 489-497 [Abstract/Free Full Text]
  51. Bishopric, N. H., Jayasena, V., and Webster, K. A. (1992) Mol. Cell. Biol. 12, 292-301 [Abstract]
  52. Kovacic-Milivojevic, B., and Gardner, D. G. (1992) Mol. Cell. Biol. 12, 292-301 [Abstract]
  53. Goswami, S. K., Zarraga, A. M., Martin, M. E., Morgenstern, D., and Siddiqui, M. A. Q. (1992) Cell. Mol. Biol. Res. 38, 49-58
  54. Shull, M. M., Pugh, D. G., and Lingrel, J. B. (1990) Genomics 6, 451-460 [Medline] [Order article via Infotrieve]
  55. Yagawa, Y., Kawakami, K., and Nagano, K. (1990) Biochim. Biophys. Acta 1049, 286-292 [Medline] [Order article via Infotrieve]
  56. Kirtane, A., Ismail-Beigi, N., and Ismail-Beigi, F. (1994) J. Membr. Biol. 137, 9-15 [Medline] [Order article via Infotrieve]
  57. Kim, D., Marsh, J. D., Barry, W. H., and Smith, T. W. (1984) Circ. Res. 55, 39-48 [Abstract]
  58. Vemuri, R., Longoni, S., and Philipson, K. D. (1989) Am. J. Physiol. 256, C1273-C1276
  59. Katz, A. M. (1994) Ann. Intern. Med. 121, 363-371 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.